09.03.24
Pharmachem Innovations, LLC, a Kearny, New Jersey-based manufacturer of nutraceutical products and solutions, has launched as an independent company after Turnspire Capital Partners LLC acquired the business from Ashland, Inc.
Pharmachem has manufacturing facilities in New Jersey, Utah, and Mexico, and produces a wide range of proprietary and private label products used in several applications, such as hydration, joint health, women’s and men’s health, and cardiovascular health.
The company also provides custom formulation and contract manufacturing services to the nutrition market, handling formula design, ingredient sourcing, and finished product manufacturing.
Maurice Murphy, operating partner with Turnspire, has been named executive chairman of the board. Murphy most recently served as CEO of UPG, another Turnspire company.
“I am thrilled to join a company as customer-centric and innovation-driven as Pharmachem,” said Murphy. “As an independent company with Turnspire’s support, we will be able to accelerate the Company’s growth through close partnerships with high-caliber customers and investments in new capabilities.”
Pharmachem also appointed Jeff Rogers, an experienced executive in the ingredients space, as interim CEO. Rogers most recently served as president and chief operating officer of Niacet, where he was responsible for leading the company’s commercial and manufacturing operations. He also held leadership roles at Ashland, Lonza, AkzoNobel, and National Starch.
“I am excited to join the Pharmachem team and build on its rich legacy as an innovator in the nutraceuticals space,” said Rogers. “We look forward to partnering with our valued customers to develop new and creative custom formulations and proprietary products. We are excited to leverage our vast capabilities to pursue a wide array of attractive growth opportunities while continuing to provide the highest-quality service for our customers.”
In addition to Murphy and Rogers, Pharmachem will be led by members of its current management team.
Pharmachem has manufacturing facilities in New Jersey, Utah, and Mexico, and produces a wide range of proprietary and private label products used in several applications, such as hydration, joint health, women’s and men’s health, and cardiovascular health.
The company also provides custom formulation and contract manufacturing services to the nutrition market, handling formula design, ingredient sourcing, and finished product manufacturing.
Maurice Murphy, operating partner with Turnspire, has been named executive chairman of the board. Murphy most recently served as CEO of UPG, another Turnspire company.
“I am thrilled to join a company as customer-centric and innovation-driven as Pharmachem,” said Murphy. “As an independent company with Turnspire’s support, we will be able to accelerate the Company’s growth through close partnerships with high-caliber customers and investments in new capabilities.”
Pharmachem also appointed Jeff Rogers, an experienced executive in the ingredients space, as interim CEO. Rogers most recently served as president and chief operating officer of Niacet, where he was responsible for leading the company’s commercial and manufacturing operations. He also held leadership roles at Ashland, Lonza, AkzoNobel, and National Starch.
“I am excited to join the Pharmachem team and build on its rich legacy as an innovator in the nutraceuticals space,” said Rogers. “We look forward to partnering with our valued customers to develop new and creative custom formulations and proprietary products. We are excited to leverage our vast capabilities to pursue a wide array of attractive growth opportunities while continuing to provide the highest-quality service for our customers.”
In addition to Murphy and Rogers, Pharmachem will be led by members of its current management team.
